Analytical SciencesThe electrochemical behavior of catecholamines involves an electron transfer-chemical reaction-electron transfer (ECE) mechanism, characterized by two reversible redox reactions interspersed with an irreversible chemical reaction. Previously, we reported
YinQiang Yin Shu +2 more
openalex +2 more sources
Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST. [PDF]
PLoS ONEBackgroundNon-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice ...
Masahiro Nomoto +10 more
doaj +2 more sources
Prescribing patterns and determinants for elderly patients with Parkinson's disease in Japan: a retrospective observational study using insurance claims databases [PDF]
Frontiers in Neurology, 2023 BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki +4 more
doaj +2 more sources
Copper oxide, ionic liquid and Mn(III) Salen modified carbon paste electrode as selective electrochemical sensor for determination of droxidopa in the presence of carbidopa [PDF]
, 2020 A novel electrochemical sensor for the selective and sensitive detection of droxidopa in presence of carbidopa at physiological pH was developed by the bulk modification of carbon paste electrode (CPE) with copper oxide (CuO), ionic liquid and Mn (III ...
Mohammad Reza Aflatoonian +5 more
openalex +2 more sources
Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde [PDF]
Clinical Chemistry, 2010 AbstractBackground: l-Threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa) is a norepinephrine (NE) prodrug under development to treat orthostatic hypotension. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an endogenous catecholaldehyde produced by enzymatic oxidative deamination of dopamine, is toxic to catecholaminergic neurons. Based on the observation of
Courtney Holmes +3 more
+6 more sources
Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension [PDF]
Journal of the American Society of Hypertension, 2016 The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo ...
Stuart Isaacson +5 more
openalex +4 more sources
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? [PDF]
Clinical Autonomic Research, 2017 Horacio Kaufmann
openalex +4 more sources
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease. [PDF]
Parkinsons Dis, 2023 Background. National as well as international Parkinson’s disease (PD) treatment guidelines are available to guide clinicians. Previous research has shown that nonmotor symptoms (NMS) are pronounced in late‐stage PD and has suggested that current treatment is insufficient and could be improved. Objectives.
Rosqvist K, Odin P.
europepmc +2 more sources
Droxidopa in neurogenic orthostatic hypotension [PDF]
Expert Review of Cardiovascular Therapy, 2015 Neurogenic orthostatic hypotension (nOH) is a fall in blood pressure (BP) on standing due to reduced norepinephrine release from sympathetic nerve terminals. nOH is a feature of several neurological disorders that affect the autonomic nervous system, most notably Parkinson disease (PD), multiple system atrophy (MSA), pure autonomic failure (PAF), and ...
Horacio Kaufmann +2 more
openalex +4 more sources
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease [PDF]
Movement Disorders Clinical Practice, 2018 Robert A Hauser, Steven Vernino
exaly +2 more sources